Cover Page

Cite item


The prevalence of HBV infection is estimated by the frequency of occurrence of HBsAg and varies depending on the geographic region. Chronic infection is characterized by a stable presence of HBsAg for 6 months, with the exception of the occult form of the disease, characterized by the absence of HBsAg, an extremely low level of HBV DNA in the blood serum. The problem of identifying occult HBV (ocHBV) is especially relevant because of the development of transplantology and transfusiology. However, serological screening of donor blood used in the Russian Federation and Central Asian countries does not reveal HBV seronegative donors. Since HBV infection is possible with the introduction of small doses of the virus, the importance of using complex molecular methods for detecting donor ocHBV is obvious, despite the low viral load, since donor blood is used predominantly in patients with severe course of various diseases characterized by increased susceptibility to HBV because of immunosuppression. The aim of our work was to study the characteristics of the genetic structure of the ocHBV in donors in Astana, Kazakhstan. A total of 500 blood plasma samples from HBsAg-negative donors were obtained in 2012 from residents of Kazakhstan, Astana. Using the method, we proposed to detect HBV DNA with a low viral load, HBV was detected in 9.4% of donors. Serological markers were found in 12.7% of patients with HBV DNA, 8.5% had HBcor IgG antibodies, 4.2% had HBcor IgG and HBe IgG antibodies at the same time. Thus, in 41 (87.3%) of the blood donor, ocHBV was seronegative. Based on the phylogenetic analysis of the 47 isolates showed that the HBV of genotype D (95.75%) prevails in the examined group in comparison with HBV of genotype A (4.25%). HBV subgenotypes are represented in the following ratios: D1 — 46.8%, D2 — 17.05%, D3 — 31.9%, A2 — 4.25%. In a comparative analysis, the distribution of HBV subgenotypes in the group with ocHBV and in the case of the manifest form in donors in the Republic of Kazakhstan significantly differed — χ2 = 14.027 at p = 0.0072, df = 4. The incidence of HBV D3 with ocHBV (31.9%) exceeded that of patients with a manifest form (7.4%). The relative risk of occult form of disease in patients with the subgenotype D3 is significantly higher (RR = 1.572, CI: 1.179–2.096, p = 0.0208). When assessing the picture of HBV diversity on the material of the group including HBsAg-negative and HBsAg-positive blood donors, it is evident that the genetic relationship of the manifestations of the manifest HBV and the ocHBV of genotype D is obvious. Among the isolates are both similar in nucleotide sequences with those previously described in various regions of Europe and Central Asia, and circulating in the territory of the Republic of Kazakhstan, which indicates an independent homologous evolution of HBV in the region. The high incidence of ocHBV among HBsAg-negative blood donors is indicative not only of the widespread prevalence of the occult form of the disease course in the population and the inadequacy for the detection of chronic HBV of conventional HBsAg and HBV DNA in the peripheral blood using commercial kits, but also the need to study the characteristics of the immune response with this form of the disease course.


About the authors

Yu. V. Ostankova

St. Petersburg Pasteur Institute, St. Petersburg

Author for correspondence.
Researcher, Laboratory of Molecular Immunology Russian Federation

A. V. Semenov

St. Petersburg Pasteur Institute, St. Petersburg;
Pavlov First St. Petersburg State Medical University, St. Petersburg;
North-Western State Medical University named after I.I. Mechnikov, St. Petersburg

PhD (Biology), Head of the Laboratory of Virology and Immunology HIV, St. Petersburg Pasteur Institute, St. Petersburg, Russian Federation; Associate Professor, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation; Associate Professor, Department of Clinical Laboratory Diagnostics, North-West State Medical University named after I.I. Mechnikov Russian Federation

Z. K. Burkitbayev

Research and Production Center of Transfusiology, Astana

PhD (Medicine), Director Kazakhstan

T. N. Savchuk

Research and Production Center of Transfusiology, Astana

Head of Department of Laboratory Studies of Transfusion Infections Kazakhstan

A. A. Totolian

St. Petersburg Pasteur Institute, St. Petersburg;
Pavlov First St. Petersburg State Medical University, St. Petersburg

RAS Full Member, PhD, MD (Medicine), Professor, Head of the Laboratory of Molecular Immunology, Director of St. Petersburg Pasteur Institute, St. Petersburg, Russian Federation; Head of the Department of Immunology, Pavlov First St. Petersburg State Medical University Russian Federation


  1. Вирусные гепатиты в Российской Федерации: аналитический обзор. СПб: ФБУН НИИЭМ имени Пастера, 2016. 152 с. [Virusnye gepatity v Rossiiskoi Federatsii: analiticheskii obzor [Viral hepatitis in the Russian Federation: an analytical review]. St. Petersburg: St. Petersburg Pasteur Instutute, 2016. 152 p.]
  2. Жибурт Е.Б., Губанова М.Н., Скорикова С.В., Буркитбаев Ж.К., Шестаков Е.А., Мамадалиев Д.М., Мадзаев С.Р. Новое в трансфузиологии (на конгрессах Международного общества переливания крови в Канкуне и Куала-Лумпуре) // Трансфузиология. 2014. Т. 15, № 3. С. 44–60. [Zhiburt E.B., Gubanova M.N., Skorikova S.V., Burkitbaev Z.K., Shestakov E.A., Mamadaliev D.M., Madzaev S.R. News in transfusion medicine (at congresses of the international society of blood transfusion in Cancun and Kuala-Lumpur). Transfuziologiya = Transfusiology, 2014, vol. 15, no. 3, pp. 44–60. (In Russ.)]
  3. Жибурт Е.Б., Мадзаев С.Р., Шестаков Е.А., Вергопуло А.А. Менеджмент крови пациента. М.: Национальный медико-хирургический центр имени Н.И. Пирогова, 2014. 64 с. [Zhiburt E.B., Madzayev S.R., Shestakov E.A., Vergopulo A.A. Menedzhment krovi patsienta [Blood management of the patient]. Moscow: National Pirogov Medical and Surgical Center, 2014. 64 p. (In Russ.)]
  4. Останкова Ю.В., Семенов А.В., Буркитбаев Ж.К., Савчук Т.Н., Тотолян А.А. Генетические варианты вируса гепатита B у первичных доноров в г. Астана, Казахстан // Инфекция и иммунитет. 2016. Т. 6, № 4. С. 359–365. [Ostankova Yu.V., Semenov A.V., Burkitbayev Z.K., Savchuk T.N., Totolian A.A. Genetic variants of hepatitis B virus in primary donors in Astana, Kazakhstan. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2016, vol. 6, no. 4, pp. 359–365. doi: 10.15789/2220-7619-2016-4-359-365 (In Russ.)]
  5. Останкова Ю.В., Семенов А.В., Файзуллаев Х.Н., Казакова Е.И., Козлов А.В., Мусабаев Э.И., Тотолян А.А. Молекулярно-биологические маркеры гепатита В у пациентов с фиброзом/циррозом печени в Узбекистане // Журнал микробиологии, эпидемиологии и иммунобиологии. 2016. № 5. С. 34–43. [Ostankova Yu.V., Semenov A.V., Faizullaev Kh.N., Kazakova E.I., Kozlov A.V., Musabaev E.I., Totolyan A.A. Molecular-biological markers of hepatitis B in patients with liver fibrosis/cirrhosis in Uzbekistan. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology Epidemiology and Immunobiology, 2016, no. 5, pp. 34–43. (In Russ.)]
  6. Полукчи Т.В., Абуова Г.Н., Батырханова С.Т. Состояние заболеваемости острыми и хроническими вирусными гепатитами в Южно-Казахстанской области // Международный студенческий научный вестник. 2016. № 4. С. 39–40. [Polukchy T.V., Abuova G.N., Batyrkhanova S.T. The incidence of acute and chronic viral hepatitis in the South Kazakhstan region. Mezhdunarodnyi studencheskii nauchnyi vestnik = International Student Scientific Bulletin, 2016, no. 4, pp. 39–40. (In Russ.)]
  7. Семенов А.В., Останкова Ю.В., Ногойбаева К.А., Касымбекова К.Т., Лаврентьева И.Н., Тобокалова С.Т., Тотолян А.А. Особенности молекулярной эпидемиологии сочетанной инфекции ВГB/ВГD в Кыргызстане // Инфекция и иммунитет. 2016. Т. 6, № 2. С. 141–150. [Semenov A.V., Ostankova Y.V., Nogoybaeva K.A., Kasymbekova K.T., Lavrentieva I.N., Tobokalova S.T., Totolyan A.A. Molecular epidemiology features of HBV/HDV co-infection in Kyrgyzstan. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2016, vol. 6, no. 2, pp. 141–150. doi: 10.15789/2220-7619-2016-2-141-150 (In Russ.)]
  8. Шайзадина Ф.М., Кошерова Б.Н., Омарова А.О. Эпидемический процесс вирусного гепатита В на территории Северо-Казахстанской области // Журнал инфектологии. 2016. Т. 8, № 3. С. 123–124. [Shayzadina F.M., Kosherova B.N., Omarov A.O. The epidemic process of viral hepatitis B in the territory of the North Kazakhstan region. Zhurnal infektologii = Journal of Infectology, 2016, vol. 8, no. 3, pp. 123–124. (In Russ.)]
  9. Шевцов А.Б., Филипенко М.Л., Киянбекова Л.С., Кравченко А.П., Омралина А.Е., Абеев А.Б., Мухамедьяров Д.А., Раманкулов Е.М. Генотипы вируса гепатита В, циркулирующие на территории г. Астана // Биотехнология. Теория и практика. 2011. № 4. С. 14–23. [Shevtsov A.B., Filipenko M.L., Kiyanbekova L.S., Kravchenko A.P., Omralina A.E., Abeev A.B., Mukhamedyarov D.A., Ramankulov E.M. Genotypes of the hepatitis B virus, circulating in the territory of Astana. Biotekhnologiya. Teoriya i praktika = Biotechnology. Theory and Practice, 2011, no. 4, pp. 14–23. (In Russ.)]
  10. Alavian S.M. Occult hepatitis B virus infection among hemodialysis patients. Hepat. Mon., 2012, vol. 12, no 4, pp. 242–243. doi: 10.5812/hepatmon.869
  11. Arauz-Ruiz P., Norder H., Robertson B.H., Magnius L.O. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J. Gen. Virol., 2002, vol. 83, no. 8, pp. 2059–2073. doi: 10.1099/0022-1317-83-8-2059
  12. Baumert T.F., Thimme R., von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol., 2007, vol. 13, no. 1, pp. 82–90. doi: 10.3748/wjg.v13.i1.82
  13. Beasley R.P., Hwang L.Y., Lee G.C., Lan C.C., Roan C.H., Huang F.Y., Chen C.L. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet, 1983, vol. 2 (8359), pp. 1099–1102.
  14. Bes M., Vargas V., Piron M., Casamitjana N., Esteban J. I., Vilanova N., Pinacho A., Quer J., Puig L., Guardia J., Sauleda S. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J. Hepatol., 2012, vol. 56, no. 4, pp. 765–774. doi: 10.1016/j.jhep.2011.11.011
  15. Bissinger A.L., Fehrle C., Werner C.R., Lauer U.M., Malek N.P., Berg C.P. Epidemiology and genotyping of patients with chronic hepatitis b: genotype shifting observed in patients from Central Europe. Pol. J. Microbiol., 2015, vol. 64, no. 1, pp. 15–21.
  16. Brichler S., Lagathu G., Chekaraou M.A., Le Gal F., Edouard A., Dény P., Césaire R., Gordien E. African, Amerindian and European hepatitis B virus strains circulate on the Caribbean Island of Martinique. J. Gen. Virol., 2013, vol. 94, iss. 10, pp. 2318– 2329. doi: 10.1099/vir.0.055459-0
  17. De Mitri M.S., Cassini R., Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur. J. Cancer., 2010, vol. 46, pp. 2178–2186. doi: 10.1016/j.ejca.2010.03.034
  18. Dufour D.R. Hepatitis B surface antigen (HBsAg) assays-are they good enough for their current uses? Clin. Chem., 2006, vol. 52, no. 8, pp. 1457–1459. doi: 10.1373/clinchem.2006.072504
  19. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. GBD 2013 Mortality and Causes of Death Collaborators. Lancet, 2015, vol. 385, no. 385 (9963), pp. 117–171. doi: 10.1016/S0140-6736(14)61682-2
  20. Hui C. K., Sun J., Au W.Y., Lie A.K., Yueng Y.H., Zhang H.Y., Lee N.P., Hou J.L., Liang R., Lau G.K. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J. Hepatol., 2005, vol. 42, iss. 6, pp. 813–819. doi: 10.1016/j.jhep.2005.01.018
  21. Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis., 1995, vol. 20, no. 4, pp. 992–1000.
  22. Jeantet D., Chemin I., Mandrand B., Tran A., Zoulim F., Merle P., Trepo C., Kay A. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J. Med. Virol., 2004, vol. 73, iss. 4, pp. 508–515. doi: 10.1002/jmv.20119
  23. Jutavijittum P., Andernach I.E, Yousukh A., Samountry B., Samountry K., Thammavong T., Keokhamphue J., Toriyama K., Muller C.P. Occult hepatitis B infections among blood donors in Lao PDR. Vox. Sang., 2014, vol. 106, iss. 1, pp. 31–37. doi: 10.1111/ vox.12073
  24. Kao J.-H. Molecular epidemiology of hepatitis B virus. Korean J. Intern. Med., 2011, vol. 26, no. 3, pp. 255–261. doi:10.3904/ kjim.2011.26.3.255
  25. Kramvis A., Paraskevis D. Subgenotype A1 of HBV – tracing human migrations in and out of Africa. Antivir. Ther., 2013, vol. 18 (3 B), pp. 513–521. doi: 10.3851/IMP2657
  26. Kumar S., Stecher G., Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol. Biol. Evol., 2016, vol. 33, iss. 7, pp. 1870–1874. doi: 10.1093/molbev/msw054
  27. Lin C.-L., Kao J.-H. Hepatitis B virus genotypes and variants. Cold Spring Harb. Perspect. Med., 2015, vol. 5, no. 5:a021436. doi: 10.1101/cshperspect.a021436
  28. Margolis H.S., Alter M.J., Hadler S.C. Hepatitis B: evolving epidemiology and implications for control. Semin. Liver Dis., 1991, vol. 11, no. 2, pp. 84–92. doi: 10.1055/s-2008-1040427
  29. McMahon B.J., Alward W.L., Hall D.B., Heyward W.L., Bender T.R., Francis D.P., Maynard J.E. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J. Infect. Dis., 1985, vol. 151, no. 4, pp. 599–603.
  30. Mulrooney-Cousins P.M, Michalak T.I. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J. Gastroenterol., 2007, vol. 13, no. 43, pp. 5682–5686. doi: 10.3748/wjg.v13.i43.5682
  31. Norder H., Couroucé A.M., Coursaget P., Echevarria J.M., Lee S.D., Mushahwar I.K., Robertson B.H., Locarnini S., Magnius L.O. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology, 2004, vol. 47, no. 6, pp. 289–309. doi: 10.1159/000080872
  32. Nurgalieva Z.Z., Hollinger F.B., Graham D.Y., Zhangabylova S., Zhangabylov A. Epidemiology and transmission of hepatitis B and C viruses in Kazakhstan. World J. Gastroenterol., 2007, vol. 13, no. 8, pp. 1204–1207. doi: 10.3748/wjg.v13.i8.1204
  33. Okamoto H., Tsuda F., Sakugawa H., Sastrosoewignjo R.I., Imai M., Miyakawa Y., Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J. Gen. Virol., 1988, vol. 69, pp. 2575–2583. doi: 10.1099/0022-1317-69-10-2575
  34. Oluyinka O.O., Tong H.V., Bui Tien S., Fagbami A.H., Adekanle O., Ojurongbe O., Bock C.T., Kremsner P.G., Velavan T.P. Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks. PLoS One, 2015, vol. 10, no. 7:e0131912. doi: 10.1371/journal.pone.0131912
  35. Pisano M.B., Blanco S., Carrizo H., Ré V.E., Gallego S. Hepatitis B virus infection in blood donors in Argentina: prevalence of infection, genotype distribution and frequency of occult HBV infection. Arch. Virol., 2016, vol. 161, no. 10, pp. 2813–2817. doi: 10.1007/s00705-016-2960-2
  36. Pollicino T., Squadrito G., Cerenzia G., Cacciola I., Raffa G., Craxi A., Farinati F., Missale G., Smedile A., Tiribelli C., Villa E., Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology, 2004, vol. 126, iss. 1, pp. 102–110. doi: 10.1053/j.gastro.2003.10.048
  37. Poorolajal J., Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J. Res. Med. Sci., 2009, vol. 14, no. 4, pp. 249–258.
  38. Pourkarim M.R., Lemey P., Amini-Bavil-Olyaee S., Houspie L., Verbeeck J., Rahman M., Maes P., Vanwijngaerden E., Nevens F., Van Ranst M. Molecular characterization of hepatitis B virus strains circulating in Belgian patients co-infected with HIV and HBV: Overt and occult infection. J. Med. Virol., 2011, vol. 83, iss. 11, pp. 1876–1884. doi: 10.1002/jmv.22174
  39. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., Craxi A., Donato F., Ferrari C., Gaeta G.B., Gerlich W.H., Levrero M., Locarnini S., Michalak T., Mondelli M.U., Pawlotsky J.M., Pollicino T., Prati D., Puoti M., Samuel D., Shouval D., Smedile A., Squadrito G., Trepo C., Villa E., Will H., Zanetti A.R., Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol., 2008, vol. 49, iss. 4, pp. 652–657. doi: 10.1016/j.jhep.2008.07.014
  40. Sarkar N., Pal A., Das D., Saha D., Biswas A., Bandopadhayay B., Chakraborti M., Ghosh M., Chakravarty R. Virological characteristics of acute hepatitis B in Eastern India: critical differences with chronic infection. PLoS One, 2015, vol. 10, no. 11: e0141741. doi: 10.1371/journal.pone.0141741
  41. Shapiro C.N. Epidemiology of hepatitis B. Pediatr. Infect. Dis. J., 1993, vol. 12, no. 5, pp. 433–437.
  42. Smolle E., Zohrer E., Bettermann K., Haybaeck J. Viral hepatitis induces hepatocellular cancer: what can we learn from epidemiology comparing Iran and worldwide findings? Hepat. Mon., 2012, vol. 12 (10 HCC):e7879. doi: 10.5812/hepatmon.7879
  43. Tallo T., Tefanova V., Priimagi L., Schmidt J., Katargina O., Michailov M., Mukomolov S., Magnius L., Norder H. D2: major subgenotype of hepatitis B virus in Russia and the Baltic region. J. Gen. Virol., 2008, vol. 89, iss. 8, pp. 1829–1839. doi: 10.1099/ vir.0.83660-0
  44. Thedja M.D., Roni M., Harahap A.R., Siregar N.C., Ie S.I., Muljono D.H. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol. Int., 2010, vol. 4, no. 3, pp. 608–614. doi: 10.1007/s12072-010-9203-5
  45. Thompson J.D. Higgins D. G., Gibson T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res., 1994, vol. 22, no. 22, pp. 4673–4680.
  46. Vaezjalali M., Rashidpour S., Rezaee H., Hajibeigi B., Zeidi M., Gachkar L., Aghamohamad S., Najafi R., Goudarzi H. Hepatitis B viral DNA among HBs antigen negative healthy blood donors. Hepat. Mon., 2013, vol. 13, no. 3:e6590. doi: 10.5812/hepatmon.6590
  47. World Health Organization. Prevention and control of viral hepatitis infection: frame work for global action. Geneva: WHO, 2012. URL: (13.12.2017)
  48. Yuen M.F., Lai C.L. Hepatitis B virus genotypes: natural history and implications for treatment. Expert. Rev. Gastroenterol. Hepatol., 2007, vol. 1, pp. 321–328. doi: 10.1586/17474124.1.2.321
  49. Yim H.J., Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatol., 2006, vol. 43, iss. S1, pp. S173–S181. doi: 10.1002/hep.20956
  50. Zerbini A., Pilli M., Boni C., Fisicaro P., Penna A., Di V. P., Giuberti T., Orlandini A., Raffa G., Pollicino T., Raimondo G., Ferrari C., Missale G. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology, 2008, vol. 134, iss. 5, pp. 1470–1481. doi: 10.1053/j.gastro.2008.02.017

Copyright (c) 2018 Ostankova Y.V., Semenov A.V., Burkitbayev Z.K., Savchuk T.N., Totolian A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies